Form 4: Atea Pharma CCO's Equity Transactions

Atea Pharmaceuticals' Chief Commercial Officer, John Vavricka, reported significant equity transactions including RSU vesting, stock option grants, and common stock sales for tax purposes.

Summary

• John Vavricka, Chief Commercial Officer of Atea Pharmaceuticals, Inc. (AVIR), reported equity transactions on January 31, 2026.
• Acquired 42,083 shares of common stock through the vesting and exercise of Restricted Stock Units (RSUs).
• Disposed of 11,570 shares of common stock at a price of $4.24 per share to cover tax liabilities related to RSU vesting.
• Received a grant of 119,520 stock options with an exercise price of $4.24 per share, expiring on January 30, 2036.
• The newly granted stock options will vest in 48 equal monthly installments, becoming fully vested by January 31, 2030.
• Following these transactions, Vavricka directly owns 82,594 shares of common stock and indirectly owns 82,508 shares through the John F. Vavricka Deed of Trust. He also directly holds 119,520 stock options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing routine executive compensation activities and pre-planned transactions under a 10b5-1 plan, with no immediate positive or negative implications for the company's operational or financial performance.

Positives

• Grant of 119,520 new stock options, aligning management incentives with shareholder value.
• Vesting of 42,083 Restricted Stock Units (RSUs), indicating achievement of prior performance or time-based criteria.

Negatives

• Sale of 11,570 shares of common stock, reducing direct beneficial ownership, although this was for tax withholding purposes.

Future Outlook

The newly granted stock options for John Vavricka will vest in 48 equal monthly installments, with full vesting expected by January 31, 2030. These options have an expiration date of January 30, 2036.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as RSU vesting and option grants, are common forms of executive compensation in the biotechnology and pharmaceutical industries. These transactions typically reflect pre-established compensation plans rather than new strategic shifts.

Stakeholder Impact

• Shareholders: Minor dilution from RSU conversion and potential future option exercise, but also aligns executive incentives.
• Management: John Vavricka's compensation structure is reinforced, providing long-term incentives.

Next Steps

• Continued monthly vesting of 119,520 stock options until full vesting on January 31, 2030.
• Potential exercise of vested stock options by John Vavricka before the January 30, 2036 expiration date.

Key Dates

Keywords

Atea Pharmaceuticals, AVIR, John Vavricka, Chief Commercial Officer, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, Share Ownership